{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T02:26:22Z","timestamp":1784168782067,"version":"3.55.0"},"reference-count":25,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2015,6,24]],"date-time":"2015-06-24T00:00:00Z","timestamp":1435104000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J Dermatology"],"published-print":{"date-parts":[[2015,7]]},"abstract":"Abstract<\/jats:title>Background<\/jats:title>The reactivation of a latent tuberculosis infection is one of the possible major events that may occur during biologic therapies for inflammatory chronic diseases such as psoriasis. Although its main screening test is regularly used in clinical practice, there are few studies about the prevalence of this silent mycobacterial infection and the rate of positive convertors during treatment.<\/jats:p><\/jats:sec>Objective<\/jats:title>To assess the prevalence of latent tuberculosis infection (LTBI<\/jats:styled-content>) in patients with moderate to severe psoriasis receiving biologic therapy by using tuberculin skin test as a screening method and to evaluate the rate of conversion of tuberculin skin test (TST<\/jats:styled-content>) during the treatment with biologics.<\/jats:p><\/jats:sec>Methods<\/jats:title>A total of 445 patients were included in our retrospective study, conducted from January 2006 to September 2012. Tuberculin skin test was performed in all patients prior to treatment and once a year during the follow\u2010up. PPD<\/jats:styled-content> was considered positive with an induration above 5\u00a0mm, following the recommendations of Centers for Disease Control and Prevention\/ America Thoracic Society. Data analysis was obtained with SPSS<\/jats:styled-content> 20.0.<\/jats:p><\/jats:sec>Results<\/jats:title>The prevalence of LTBI<\/jats:styled-content> in our population before initiating the treatment was 4.5% by using TST<\/jats:styled-content> screening method. During the treatment, 10 cases that were initially TST<\/jats:styled-content>\u2010negative became positive. Only one of the patients developed active tuberculosis infection.<\/jats:p>The other 9 TST<\/jats:styled-content>\u2010positive patients were detected during the regular annual screening, and no symptoms or findings on chest x\u2010ray were seen. All the patients were treated with isoniazid (INH<\/jats:styled-content>) for nine\u00a0months, and biologic therapy was restarted after one\u00a0month of treatment with INH<\/jats:styled-content> without development of overt TB<\/jats:styled-content> infection in any of them during the follow\u2010up period of the study. The mean time to becoming TST<\/jats:styled-content> positive from start date was 26.7\u00a0months (range from 8\u00a0months to 5\u00a0years). As the PPD<\/jats:styled-content> was done annually, it is unknown exactly when the patients became TST<\/jats:styled-content> positive. Prior to initiating treatment, 20 patients were found to be TST<\/jats:styled-content> positive. All patients had clear chest x\u2010rays and were treated with nine\u00a0months of INH<\/jats:styled-content> prior to initiating biologic therapy at least month later.<\/jats:p><\/jats:sec>Conclusions<\/jats:title>The use of a screening tool for LTBI<\/jats:styled-content> is mandatory in patients taking biologic therapies to avoid severe infectious complications. Periodic follow\u2010up is also crucial as positive results may be seen after prolonged use of these agents.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ijd.12679","type":"journal-article","created":{"date-parts":[[2015,6,24]],"date-time":"2015-06-24T23:03:36Z","timestamp":1435187016000},"page":"846-852","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Prevalence of latent tuberculosis infection in patients with moderate to severe psoriasis taking biologic therapies in a dermatologic private practice in Miami, Florida"],"prefix":"10.1111","volume":"54","author":[{"given":"Carolina","family":"Medina\u2010Gil","sequence":"first","affiliation":[{"name":"Department of Dermatology University of Miami Hospital Miami FL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Dehesa","sequence":"additional","affiliation":[{"name":"Department of Dermatology University of Miami Hospital Miami FL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriane","family":"Vega","sequence":"additional","affiliation":[{"name":"Department of Dermatology University of Miami Hospital Miami FL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Kerdel","sequence":"additional","affiliation":[{"name":"Department of Dermatology University of Miami Hospital Miami FL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,6,24]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.168.9.4620"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2012.11142.x"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1086\/383317"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2009.09331.x"},{"key":"e_1_2_5_6_1","unstructured":"World Health Organization.Global Tuberculosis Report 2013. URLhttp:\/\/apps.who.int\/iris\/bitstream\/10665\/91355\/1\/9789241564656_eng.pdf."},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2009.09505.x"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0001-7310(09)71257-8"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.21043"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.03.023"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.100623"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.090150"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-008-1007-9"},{"issue":"89","key":"e_1_2_5_14_1","first-page":"82","article-title":"Screening and monitoring of latent tubercular infection in patients taking tumor necrosis factor\u2010alfa blockers for psoriatic arthritis","volume":"39","author":"Sanduzzi A","year":"2012","journal-title":"J Rheumatol"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-012-2049-6"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2012.12.966"},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.2508001"},{"issue":"15","key":"e_1_2_5_18_1","first-page":"1","article-title":"Guidelines for the investigation of contacts of persons with infectious tuberculosis. Recommendations from the National Tuberculosis Controllers Association and CDC","volume":"54","author":"CDC","year":"2005","journal-title":"MMWR"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.029041"},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.1159\/000222431"},{"key":"e_1_2_5_21_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-1106"},{"key":"e_1_2_5_22_1","first-page":"1271","article-title":"Usefulness of enzyme\u2010linked immunospot assay (elispot) compared to tuberculin skin testing for latent tuberculosis screening in rheumatic patients scheduled for anti\u2010tumor necrosis factor treatment","volume":"35","author":"Vassilopoulos D","year":"2008","journal-title":"J Rheumatol"},{"key":"e_1_2_5_23_1","first-page":"770","article-title":"Comparison\u00a0of an in vitro tuberculosis interferon\u2010gamma\u00a0assay with delayed\u2010type hypersensitivity testing for detection of Mycobacterium tuberculosis: a pilot study in rheumatoid arthritis","volume":"35","author":"Greenberg JD","year":"2008","journal-title":"J\u00a0Rheumatol"},{"key":"e_1_2_5_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-008-8082-3"},{"key":"e_1_2_5_25_1","first-page":"S126","article-title":"Tuberculosis and opportunistic infections relevance to biologic agents","volume":"22","author":"Bieber J","year":"2004","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_5_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-012-0192-7"}],"container-title":["International Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fijd.12679","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ijd.12679","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T14:34:53Z","timestamp":1696343693000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ijd.12679"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6,24]]},"references-count":25,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["10.1111\/ijd.12679"],"URL":"https:\/\/doi.org\/10.1111\/ijd.12679","archive":["Portico"],"relation":{},"ISSN":["0011-9059","1365-4632"],"issn-type":[{"value":"0011-9059","type":"print"},{"value":"1365-4632","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6,24]]},"assertion":[{"value":"2013-04-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-02-02","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-06-24","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}